Vandetanib gets FDA approval for the treatment of advanced Medullary carcinoma thyroid
Sunday, April 24 2011 @ 10:43 am IST
Contributed by: Admin
who are not fit enough to undergo abalative surgical procedures. Vandetanib has its own share of
complications which include:
2. Elevated blood pressure
4. Loss of appetite
5. Abdominal pain
7. Skin rashes
Medullary thyroid cancer makes up approximately 3% of all thyroid cancers. The cancer starts in the C cells of the thyroid.
Cancers that begin in the C cells make extremely high levels of calcitonin. This type of thyroid cancer develops slowly.
FDA study showed that for those on vandetanib, progression-free survival averaged 22.6 months,
compared to 16.4 months for those on the placebo. The FDA says it is too early
to determine whether the vandetanib patients will live longer than the placebo ones.